Introduction {#s1}
============

Neural tube defects (NTDs) refer to a group of serious defects and its etiology is multifactorial, involving the genetic and environmental factors [@pone.0086145-Au1]. As a maternal nutrition factor, inositol plays a vital role in the development of neural tube. An epidemiological study conducted by Groenen et al showed that serum levels of inositol in NTDs-affected pregnant women were significantly lower than that of healthy pregnant women and pregnant women with lower serum levels of inositol are more susceptible to NTDs by 2.6 fold [@pone.0086145-Groenen1]. In animal studies, inositol can reduce the incidence of spina bifida in the genetic model of folate-resistant NTDs [@pone.0086145-Greene1]. The study from E. Albert Reece et al showed that supplementation of inosotol (0.08 mg/d) to pregnant mice reduced the incidence of NTDs to the next generations from 20.4% to 9.5% [@pone.0086145-Reece1]. Recently, myo-inositol soft gelatin capsules are considered as the preventive treatment of NTDs in folate-resistant subjects [@pone.0086145-DeGrazia1]. In a word, results suggest that as a nutritional substance, inositol is closely related to the development of NTDs.

ITPK1 is a pivotal regulatory enzyme in the synthesis of inositol tetraphosphate (IP~4~), inositol pentakisphosphate (IP~5~), inositol hexakisphosphate (IP~6~). ITPK1 catalyzes the inositol 1,3,4-trisphosphate\[I(1,3,4)P~3~\] into the IP~4~ which is further transformed to IP~5~ by a 5-kinase and to IP~6~ by a 2-kinase[@pone.0086145-Wilson1]--[@pone.0086145-Verbsky1]. These products regulate various cellular processes. IP~4~ inhibits the permeability of CLC3 channel and participates in the cellular signal transduction pathway; while IP~6~ is an intracellular signaling molecule, participating in the regulation of ion channels, exocytosis, endocytosis, transcription, DNA synthesis and RNA transport. Silencing or over-expression of *ITPK1* gene affected the levels of its downstream products, IP~4~, IP~5~ and IP~6~, resulting in inositol metabolic disorder [@pone.0086145-Verbsky2]. The animal experiments demonstrated that *ITPK1* was expressed in the highest level in brain and the mice with reduced levels of ITPK1 developed NTDs [@pone.0086145-Wilson2]. The structure and function changes of *ITPK1* induced by polymorphisms might affect the metabolism of salt, fluid and endocrine in cell which lead to the abnormality cell proliferation, differentiation and apoptosis, therefore disrupting the normal development of neural tube. In conclusion, *ITPK1* gene might be closely correlated with NTDs.

Previous studies indicated that maternal inositol level played an important role in NTD susceptibility. These researches were focused on animal and cell models and the population studies about the *ITPK1* gene were still lack. Weather the different susceptibility is caused by the polymorphism of the key gene *ITPK1* has not been reported. For this reason, we genotyped the polymorphism of *ITPK1* gene and tested maternal plasma IP~6~ level to assess the potential impact of the maternal *ITPK1* genotypes on the inositol parameter and on the NTD risk in the high-risk area of Lvliang, Shanxi Province in China.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

The study protocol was reviewed and approved by the Ethics Committees Review Board of Capital Institute of Pediatrics, Beijing, China. We obtained written informed consent from all parents.

Study Population {#s2b}
----------------

We conducted a hospital-based case--control study from 2004 to 2009 in Shanxi Province in Northern China which have an NTD prevalence of 199.38 per 10,000 births [@pone.0086145-Gu1]. Effective sample sizes (320 controls VS 200 cases) for case-control study were calculated by Quanto 1.1 ver. software and the power was set at 80% [@pone.0086145-Natarajan1]. We chose 200 pregnant women with NTDs diagnosed with B-ultrasound examination. The pathological diagnosis of NTDs was completed by experienced pathologists according to the International Classification of Diseases, Tenth Revision, codes Q00 anencephaly, Q05 spina bifida, and Q01 encephalocele (<http://apps.who.int/classifications>). As for control group, women who had a live-born infant with no identified structural malformation after 1-year follow-up and who aborted for nonmedical reasons were enrolled from this region. The nonmedical aborted fetus also underwent the pathological anatomy. Any fetuses displaying pathological malformations or intrauterine growth retardation were excluded from the control group. When pregnant women were recruited, their clinical information was collected and recorded. Generally, 2 ml of venous blood was collected and stored at −20°C in local hospitals before shipping, on ice, to the study laboratories. Samples were not thawed until analysis. The population of our study was extragenetic and specifically selected and we have avoided the false positive results caused by population stratification. The collection of the samples was strictly controlled. We only had collected "anencephaly", "spina bifida" and "encephalocele", and there were not any other defects.

To validate the mRNA levels of the different SNPs, we recruited 60 healthy pregnant women (22--24 gestational weeks) from the Beijing Obstetrics and Gynecology Hospital, and collected the 2.5 ml venous blood in a PAXgene Blood RNA Tube (BRT). Immediately after blood collection, the PAXgene® Blood RNA Tube was gently inverted 8--10 times and stored the PAXgene® Blood RNA Tube upright at room temperature (18°C to 25°C) for a minimum of 2 hours. After that, the tube was then transferred to freezer (−20°C) before shipping, on ice, to the study laboratories.

DNA Extraction {#s2c}
--------------

Genomic DNA was extracted from frozen blood samples using the Blood DNA Kit (Qiagen, Germany) according to the manufacturer's instructions and was subsequently used for genotyping. DNA concentration and purity were determined by absorbance at 260 nm and 280 nm.

RNA Extraction {#s2d}
--------------

Genomic RNA was extracted from frozen blood samples using PAXgene Blood RNA Kit (Qiagen, Germany) according to the manufacturer's protocol and was subsequently used for RT-PCR. RNA concentration and purity were determined by absorbance at 260 nm and 280 nm.

Single-Nucleotide Polymorphism Selection {#s2e}
----------------------------------------

In our study, tag SNPs were selected from the Haploview software 4.2 (Mark Daly's lab of Broad Institute, Cambridge, MA, Britain) [@pone.0086145-Barrett1] using HapMap Genome Browser release\#24 (Phase 1 & 2 - full dataset ) data [@pone.0086145-Smith1] based on the CHB+JPT population and dbSNPs (<http://www.ncbi.nlm.nih.gov/projects/SNP/>) databases by the criterion that minor allele frequencies \>0.2, pairwise correlation *r^2^*\>0.8, giving first priority to those in coding exons, and then those underlying regulatory elements. Combined with the principles of Sequenom genotyping primer design, 13 tag SNPs were finally selected.

Genotyping Approach {#s2f}
-------------------

All cases and controls were genotyped for the selected SNPs of the *ITPK1* gene were using Sequenom MassARRAY System with matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (Sequenom, San Diego, California). Two primers for Polymerase chain reaction (PCR) amplification and one primer for extension primers were designed using RealSNP (<https://www.mysequenom.com/>). Approximately 20 ng of genomic DNA was used to genotype each sample. The data were analyzed using Type Analysis 4.0. We had done the validation study about the genotyping accuracy in *ITPK1* gene. The Sequenom genotyping platform is medium-throughput. In order to ensure the genotyping consistency, 10% of samples were re-genotyped, and another 10% of samples were sequenced directly to validate the accuracy of the genotyping. Sequencing results were exported to Mutation Surveyor Version 3.25 (Softgenetics, State College, PA, USA; <http://www.softgenetics.com>) for alignment and multiple comparisons. Genotyping quality control study contained 1 blank sample, 2 repeated samples, and a \>90% of genotyping call rate.

Prediction Transcription Factor and Function Tests {#s2g}
--------------------------------------------------

We predicted the binding capacity to potential transcription factor for the different genotypes in the four positive tag SNPs using the bioinformatics method (<http://www.gene-regulation.com/pub/programs/alibaba2/index.html>) and found the AA genotype of rs3783903 was located in the conserved sequence of approximate transcription factors (AP-1) and there were not any other predicted transcription factor binding sites in the oligo of rs3783903. The other 3 sites were also analyzed and the results showed that they were located in the non-conserved sequences of the transcription factor binding sites. Then we applied EMSA to detect whether the rs3783903 polymorphism could change the binding ability of the sequence to the transcription factor AP-1.

Determination of IP~6~ in Maternal Plasma {#s2h}
-----------------------------------------

The plasma concentration of inositol (IP~6~) was detected according to the protocol of the previous study [@pone.0086145-Tur1]. The 200 ul plasmas were transferred into the EP tubes; 20 ul of 0.1M EDTA and 20 ul of 6.1N trichloroacetic acid were added into the tubes. Then the mixture was vortexed and centrifuged at 5200 g for 10 min at 4°C. The supernatant (60 ul) was collected and added the 60 ul of 50 mM TEAA buffer, pH9. Mixtures were vortexed and taken the 50 ul sample was injected into the LC-MS apparatus (system 1). We selected 60 subjects from spina bifida groups and controls, respectively.

Nuclear Extracts and Electromobility Shift Assay (EMSA) {#s2i}
-------------------------------------------------------

Nuclear Extracts from Hela cells were prepared following the instructions and the protocol (NE-PER Nuclear and Cytoplasmic Extraction Reagents). To determine the crucial role of the rs3783903 at the region of the *ITPK1* intron, the oligonucleotides containing the nucleotide A or G at rs3783903 was designed. The AP-1 core sequence was (5′-AGTCA-3′). The sequences for these double-stranded oligonucleotides were: the probes biotinylated at the 5′ end (Sangon Biotech (Shanghai) Co, Ltd ), A (5′-tgaaagtgc[Agtcaagatggtag]{.ul}-3′) and G (5′-tgaaagtgc[Ggtcaagatggtag]{.ul}-3′). The oligonucleotides were incubated for 20 min with an equal amount of nuclear extracts in the presence of 10% glycerol, 1 ul dIdC, binding buffer. A 200-fold excess of A or G cold probes non biotinylated at the 5′ end were used in competiton assays. The DNA-protein complexes were run on a 6% acrylamide gel and transferred to a N+ nylon membrane, cross-linked and revealed by chemiluminescence (Light Shift Chemiluminescent EMSA kit, Pierce). We used protein-specific supershift antibodies, anti-c-jun (H-79, sc-1694) and anti-c-fos (sc-52) antibodies (Santa Cruz CA, USA), to identify the components of the AP-1 transcription factor in the DNA--protein complex. These antibodies were incubated with the nuclear extracts for 30 min at room temperature before incubation with those probes. Besides, the unlabeled mutant probe was added to the wild-type labeled probe lane.

Validation of the Differentially Expressed Genotypes by Quantitative Real-time PCR (RT-PCR) {#s2j}
-------------------------------------------------------------------------------------------

Total RNA was extracted from the peripheral blood of the healthy women using QIAamp® RNA Blood Mini Handbook Kit(QIAamp®). Real-time qPCR analysis was performed at CWBio.Co. Ltd. (Beijing, China). Briefly, the NEB E. coli poly (A) polymerase was firstly used to add poly (A) tail to total RNA. Complementary DNA was synthesized by using the SuperRT Two Step RT-PCR Kit reverse transcriptase (CWbio.Co, Ltd) and mRNA specific reverse transcription primers. SYBR Green (UltraSYBR Mixture, CWbio.Co Ltd) uptake in double-stranded DNA was measured using ABI 7500 Sequence Detection System in the presence of SYBR-Green. We calculated *ITPK1* (Forward: ACCGCTCCAAGTCCTATGAG Reverse: GGGAAAGTCAAGCCGTTCTTC) and used this statistic to determine relative gene expression. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control gene (Forward: ATGGGGAAGGTGAAGGTCG; Reverse: GGGGTCATTGATGGCAACAATA).

Statistical Analysis {#s2k}
--------------------

The genotype frequency of SNP was tested for Hardy-Weinberg equilibrium (HWE) in cases and controls by the Chi-square test. The indicator of linkage disequilibrium (LD), r^2^ (square of correlation coefficient), and the haplotype frequencies were analyzed using online SNPstats software at <http://bioinfo.iconcologia.net/SNPstats> [@pone.0086145-Sole1]. General characteristics of the participants were presented as the mean and standard deviations (SDs) for continuous measures, while frequencies and percentages were used for categorical measures. Association of genetic polymorphisms of *ITPK1* gene with NTD risk was analyzed using univariate analysis through Chi-square test and Fisher's exact test. The correlation between each SNP and NTDs risk was estimated by logistic regression analysis with adjustment for other variables. MACH [@pone.0086145-Sanna1], [@pone.0086145-Willer1] was used to impute the un-genotyped SNPs in *ITPK1* locus, using the reference panel ASN data (1000 Genomes Integrated Phase 1). Association test was performed by using logistic regression. The statistical analysis was conducted using SPSS statistical analysis software, version 17.0 (SPSS, Chicago, IL, USA). Association was expressed as odds ratios (*OR*) with 95% confidence intervals (*CI*). The association was considered to be significant when the *P*-value was\<0.05.

Results {#s3}
=======

General Characteristics of the Participants {#s3a}
-------------------------------------------

We recruited 200 cases and 320 matched controls and conducted a hospital-based case--control study in the Lvliang mountain area of Shanxi Province in northern China and preliminarily investigated the association between *ITPK1* gene and NTDs. There were 101 anencephaly cases, 80 spina bifida cases and 19 encephalocele cases. The average genotyping call rate was \>90% in all samples. Re-genotyping results showed a 100% concordance. The general characteristics of the participants are shown in [Table 1](#pone-0086145-t001){ref-type="table"}. There was no significant difference between groups in maternal age, mother's educational level, gravidity, parity and periconceptional folic acid use. The gestational week of controls was lower than that of cases.

10.1371/journal.pone.0086145.t001

###### The general characteristics of the study subjects.

![](pone.0086145.t001){#pone-0086145-t001-1}

  Characteristics                        Case (N = 200[a](#nt101){ref-type="table-fn"}, %[b](#nt102){ref-type="table-fn"})   Control (N = 320[a](#nt101){ref-type="table-fn"}, %)   *P* [c](#nt103){ref-type="table-fn"}
  ------------------------------------- ----------------------------------------------------------------------------------- ------------------------------------------------------ --------------------------------------
  Age (year)                                                                    194                                                                  325                           
  \<20                                                                       14 (7.2)                                                              25 (7.7)                                        0.112
  20--29                                                                    147 (75.8)                                                            220 (67.7)                       
  \>29                                                                        33 (17)                                                             80 (24.6)                        
  Educational level                                                             190                                                                  301                           
  \< Middle school graduation                                                15 (7.9)                                                             35 (11.6)                                        0.199
  Middle school graduation                                                  142 (74.7)                                                            203 (67.4)                       
  \> Middle school graduation                                                33 (17.4)                                                            63 (20.9)                        
  Gravidity (n)                                                                 187                                                                  302                           
  1                                                                           13 (7)                                                              31 (10.3)                                         0.45
  2                                                                          20 (10.7)                                                             33(10.9)                        
  ≥3                                                                        154 (82.3)                                                            238 (78.8)                       
  Parity (n)                                                                    186                                                                  299                           
  0                                                                         23 (10.22)                                                            30 (10.04)                                       0.316
  1                                                                          13 (7.30)                                                            32 (10.78)                       
  ≥2                                                                        150 (82.48)                                                          237 (79.18)                       
  Periconceptional folic acid use                                               166                                                                  280                           
  No [d](#nt104){ref-type="table-fn"}                                       156 (93.9)                                                            271 (96.8)                                       0.156
  Yes                                                                        10 (6.1)                                                              9 (3.2)                         
  Gestational week                                                              195                                                                  304                           
  \<21                                                                      108 (55.4)                                                            200 (65.8)                                       0.041
  21--29                                                                     58 (29.7)                                                             76 (25)                         
  ≥30                                                                        29 (14.9)                                                             28 (9.2)                        

^a^ Referes to the number of subject.

^b^ Percentages may not equal 100 because of rounding.

^c^ Chi-square test was used to calculate the p values.

^d^ The "periconceptional" refer to the month before conception and the first 3 months after conception.

Association of Genetic Polymorphisms of *ITPK1* Gene with NTDs Risk {#s3b}
-------------------------------------------------------------------

The 13 tag SNPs of *ITPK1* gene were genotyped and all polymorphisms were in Hardy-Weinberg equilibrium. The study showed that the four tag SNPs were significantly different between cases and controls ([Table S1](#pone.0086145.s001){ref-type="supplementary-material"}). While anencepahly and spina bifida might be considered as primary neurulation defects, and encephaloceles as post-neurulation defects, we removed the encephaloceles from the analysis. Meanwhile, anencepahly and spina bifida were separately analyzed in subtypes. We re-analyzed the cases and controls and found that the statistical differences were more significant. Four SNPs (rs4586354, rs3783903, rs2236131, and rs1740689) had a high odds ratio index for NTDs ([Table 2](#pone-0086145-t002){ref-type="table"}). MACH was used to impute the un-genotyped SNPs in *ITPK1* locus, using the reference panel ASN data (1000 Genomes Integrated Phase 1). Association test was performed by using logistic regression. Results showed that 64 SNPs were statistically significant (*P-value* from 5E-02 to 3.25E-08) and were in the non-coding areas, among which rs882023, rs10132322 and rs8013870 were located in the meaningful regions of the intron ([Table 3](#pone-0086145-t003){ref-type="table"}). Four tag SNPs of *ITPK1* gene were analyzed, and showed that a LD was observed between all loci in this study population using <http://analysis2.bio-x.cn/myAnalysis.php>. Compared with the wild-haplotype CGAG, the TAGA haplotype had a significantly higher risk of NTDs (*OR* = 1.64, 95%*CI* \[1.15--2.33\], *P* = 0.006) ([Table 4](#pone-0086145-t004){ref-type="table"}, [Figure 1](#pone-0086145-g001){ref-type="fig"}).

![LD patterns of SNPs rs4586354, rs3783903, rs2236131 and rs1740689.\
The linkage patterns between the statistical difference four SNPs in all samples. The numbers in diamond represent the 100×D′ in the form of standard color scheme. The upper bar denotes the relative distance among the SNPs. The bright red box denotes D′ = 1 and LOD≥2; the pink box denotes D′\<1 and LOD≥2.](pone.0086145.g001){#pone-0086145-g001}

10.1371/journal.pone.0086145.t002

###### The positive tag SNPs genotypes and allele frequencies in NTDs and controls.

![](pone.0086145.t002){#pone-0086145-t002-2}

  SNP          Genotype/Allele   Cases (%)    Controls (%)   *P* [a](#nt106){ref-type="table-fn"}   *OR*    *OR(95%CI)*
  ----------- ----------------- ------------ -------------- -------------------------------------- ------ ----------------
  rs4586354          TT          81 (47.4)     164 (54.1)                                            1    
                     CT          70 (40.9)     123 (40.6)                    0.48                   1.15   \[0.77,1.71\]
                     CC          20 (11.7)      16 (5.3)                    0.009                   2.53   \[1.25,5.10\]
                    CT+CC        90 (52.6)     139 (45.9)                    0.15                   1.31   \[0.90,1.91\]
                      T          232 (67.8)    451 (74.4)                                            1    
                      C          110 (32.2)    155 (25.6)                    0.03                   1.38   \[1.03,1.85\]
  rs3783903          AA          74 (40.9)     165 (52.2)                                            1    
                     AG          87 (48.1)      136 (43)                     0.07                   1.43   \[0.97,2.09\]
                     GG           20 (11)       15 (4.7)                    0.002                   2.97   \[1.44,6.13\]
                    AG+GG        107 (57.5)    151 (47.8)                   0.015                   1.58   \[1.09,2.28\]
                      A          235 (64.9)    466 (73.7)                                            1    
                      G          127 (35.1)    166 (26.3)                   0.003                   1.52   \[1.10,2.00\]
  rs2236131          GG          78 (44.3)      181 (58)                                             1    
                     AG          79 (44.9)     115 (36.9)                   0.019                   1.59   \[1.08,2.35\]
                     AA          19 (10.8)      16 (5.1)                    0.004                   2.76   \[1.35,5.64\]
                    AG+AA        98 (55.7)     138 (42.3)                   0.008                   1.65    \[1.13,2.4\]
                      G          235 (66.8)    477 (76.4)                                            1    
                      A          117 (33.2)    147 (23.6)                   0.001                   1.62   \[1.20,2.15\]
  rs1740689          AA          55 (31.6)     139 (44.3)                                            1    
                     AG          88 (50.6)     143 (45.5)                   0.043                   1.55   \[1.03,2.30\]
                     GG          31 (17.8)     32 (10.2)                    0.002                   2.45   \[1.36,4.40\]
                    AG+GG        119 (68.4)    175 (55.8)                   0.006                   1.7    \[1.16,2.54\]
                      A          198 (56.9)     421 (67)                                             1    
                      G          150 (43.1)     207 (33)                    0.002                   1.54   \[1.17, 2.02\]

Abbreviations: NTD, neural tube defect; SNP, single-nucleotide polymorphism; *OR*, odds ratio; *CI*, confidence interval.

^a^ The *P* value remained significant after Bonferroni correction at 0.05 levels.

10.1371/journal.pone.0086145.t003

###### The results of imputation and association test for the SNPs in *ITPK1* locus.

![](pone.0086145.t003){#pone-0086145-t003-3}

  SNP            Position   Allele   MAF in Cases   MAF in Controls   *OR*   Standard Error   *P*-value                     Type
  ------------- ---------- -------- -------------- ----------------- ------ ---------------- ----------- ------------------------------------------
  rs882023       93532014    T/C        0.429           0.3258        1.82        0.16        1.59E-04    int us2k[a](#nt108){ref-type="table-fn"}
  rs10132322     93487943    G/A        0.3657          0.2776        1.93        0.18        2.52E-04    int trp[b](#nt109){ref-type="table-fn"}
  rs8013870      93518403    A/G        0.4311          0.3701        1.35        0.15        3.86E-02                    int trp
  rs55948122     93484627    T/C        0.312           0.2045        3.48        0.23        3.25E-08                      int
  rs3783902      93482450    A/G        0.3323          0.2209        3.26        0.22        4.37E-08                      int
  rs56857003     93482868    G/C        0.3346          0.2239        3.26        0.23        4.70E-08                      int
  rs3783904      93482298    G/A        0.3325          0.2255        3.29        0.23        7.00E-08                      int
  rs12433984     93482709    G/A        0.3369          0.2277        3.19        0.22        7.36E-08                      int
  rs3783905      93482211    C/T        0.3304          0.2239        3.26        0.23        8.22E-08                      int
  rs55919031     93452687    C/T        0.3068          0.2184        2.71        0.23        6.43E-06                      int
  rs7154944      93450468    T/G        0.3105          0.2233        2.65        0.23        9.28E-06                      int
  rs4905020      93447573    A/C        0.3092           0.222        2.63        0.22        1.00E-05                      int
  rs1815226      93439195    C/A        0.3074          0.2197        2.58        0.22        1.18E-05                      int
  rs3783915      93446992    C/T        0.3098          0.2234        2.58        0.22        1.36E-05                      int
  rs3783916      93441153    C/T        0.3098          0.2234        2.56        0.22        1.47E-05                      int
  rs55652648     93445141    G/A        0.3099          0.2237        2.56        0.22        1.49E-05                      int
  rs3783918      93439911    A/G        0.3095          0.2231        2.55        0.22        1.55E-05                      int
  rs4905016      93438765    C/G        0.309           0.2226        2.47        0.22        2.15E-05                      int
  rs12589194     93438410    T/C        0.3073           0.22         2.44        0.21        2.23E-05                      int
  rs3783919      93437614    A/G        0.3071          0.2199        2.43        0.21        2.30E-05                      int
  rs3825684      93437581    C/G        0.3073          0.2197        2.42        0.21        2.32E-05                      int
  rs67182772     93437363    T/C        0.3068          0.2195        2.41        0.21        2.49E-05                      int
  rs61446566     93436493    C/T        0.3064           0.219        2.4         0.21        2.56E-05                      int
  rs58809802     93550093    A/G        0.2913          0.2047        2.4         0.21        2.74E-05                      int
  rs57854715     93432730    T/A        0.3021          0.2137        2.34        0.21        2.98E-05                      int
  rs12587187     93435452    A/G        0.3063          0.2193        2.36        0.21        3.11E-05                      int
  rs4905017      93438821    C/A        0.3175          0.2357        2.46        0.22        3.62E-05                      int
  rs72704295     93430316    T/C        0.3015          0.2136        2.28        0.2         4.10E-05                      int
  rs8022484      93430003    G/A        0.3014          0.2137        2.28        0.2         4.33E-05                      int
  rs2295392      93429060    A/G        0.3023          0.2141        2.23        0.2         5.24E-05                      int
  rs58887679     93528433    T/C        0.3228          0.2168        1.88        0.16        8.13E-05                      int
  rs56159253     93528802    G/T        0.3221          0.2167        1.87        0.16        8.99E-05                      int
  rs1612612      93497111    A/G        0.3457          0.2487        1.96        0.17        9.91E-05                      int
  rs55901898     93529066    A/G        0.3219          0.2172        1.86        0.16        1.07E-04                      int
  rs10144329     93487652    C/T        0.3825           0.288        1.96        0.18        1.24E-04                      int
  rs1740598      93499081    T/C        0.3553          0.2585        1.92        0.17        1.33E-04                      int
  rs10144603     93487894    C/T        0.383           0.2902        1.97        0.18        1.34E-04                      int
  rs56041593     93544162    C/T        0.3154           0.227        2.02        0.19        1.49E-04                      int
  rs12587868     93494030    A/G        0.3731           0.278        1.9         0.17        1.64E-04                      int
  rs117634531    93525019    T/C        0.3905          0.3006        1.92        0.18        2.27E-04                      int
  rs10147739     93490742    T/C        0.383           0.2882        1.86        0.17        2.28E-04                      int
  rs55663734     93510695    G/C        0.3787          0.2883        1.8         0.17        4.49E-04                      int
  rs1740693      93510644    G/C        0.3785          0.2878        1.78        0.17        4.88E-04                      int
  rs1740694      93510531    A/G        0.382           0.2918        1.76        0.17        5.77E-04                      int
  rs1740594      93512947    C/G        0.3963          0.3055        1.75        0.16        5.92E-04                      int
  rs4905027      93467174    T/G        0.4137          0.4968        0.54        0.18        6.26E-04                      int
  rs1740695      93498375    A/G        0.3936          0.3015        1.73        0.16        6.41E-04                      int
  rs1740599      93498230    C/T        0.3935          0.3014        1.72        0.16        6.54E-04                      int
  rs1740696      93498149    C/T        0.3933          0.3014        1.72        0.16        6.68E-04                      int
  rs2236131      93540906    A/G        0.3293          0.2322        1.66        0.15        7.20E-04                      int
  rs3783903      93482323    G/A        0.3496          0.2612        1.6         0.15        1.92E-03                      int
  rs12589470     93426405    A/C        0.3163          0.2402        1.69        0.17        2.26E-03                      int
  rs12437283     93412166    T/C        0.4074          0.4754        0.61        0.18        5.07E-03                      int
  rs1740689      93544174    G/A        0.4192          0.3336        1.48        0.14        5.29E-03                      int
  rs2749507      93528759    A/G        0.5047          0.4257        1.45        0.14        9.45E-03                      int
  rs72704291     93420199    G/A        0.3387          0.2668        1.49        0.15        9.58E-03                      int
  rs1740691      93529213    A/C        0.5033          0.4257        1.45        0.14        9.78E-03                      int
  rs72704292     93423970    A/G        0.3304          0.2576        1.48        0.15        9.80E-03                      int
  rs2749509      93528114    A/G        0.5046          0.4255        1.43        0.14        1.02E-02                      int
  rs57933052     93416067    T/C        0.3414          0.2714        1.48        0.16        1.13E-02                      int
  rs61100258     93414467    G/A        0.3497           0.281        1.49        0.16        1.16E-02                      int
  rs2749508      93528319    C/T        0.5056           0.429        1.42        0.14        1.26E-02                      int
  rs3783924      93413261    C/T        0.3464          0.2789        1.48        0.16        1.30E-02                      int
  rs184040115    93524881    C/T        0.4607          0.3945        1.4         0.15        2.33E-02                      int

Abbreviations: *OR*, odds ratio.

^a^ Int us2k: upstream-variant-2KB sequence variant within 2KB 5′ of gene.

^b^ Int trp: triplex forming sequences.

10.1371/journal.pone.0086145.t004

###### Haplotype of 4 SNPs rs4586354, rs3783903, rs2236131 and rs1740689 in *ITPK1* gene and their relative risks for NTDs.

![](pone.0086145.t004){#pone-0086145-t004-4}

  Haplotype         rs4586354   rs3783903   rs2236131   rs1740689   Frequency    *OR(95%CI)*      *P*
  ---------------- ----------- ----------- ----------- ----------- ----------- ---------------- --------
  Wild-Haplotype        T           A           G           A        0.5454           1         
  Mut-Haplotype         C           G           A           G        0.1898     1.64(1.15,233)   0.0063

Abbreviations: NTD, neural tube defect; *OR*, odds ratio; 95% *CI,* 95% confidence interval.

It has been reported that the different polymorphisms may hold different degrees of significance for the various NTD phenotypes [@pone.0086145-Relton1]. So we analyzed the association of the *ITPK1* polymorphisms with NTD phenotypes (anencephaly, spina bifida). The subtypes were based on those devised by Cabaret et al [@pone.0086145-Cabaret1]. The research found that in the spina bifida group, individuals with the heterozygosis genotype were at a significantly increased risk for NTDs, compared with the wide type genotype ([Table 5](#pone-0086145-t005){ref-type="table"}). In our study, the subtypes of spina bifida mainly include Q05.0 cervical spina bifida with hydrocephalus (3.75%), Q05.1 thoracic spina bifida with hydrocephalus (30%), Q05.2 lumbar spina bifida with hydrocephalus (43.75%), Q05.3 sacral spina bifida with hydrocephalus (3.75%), Q05.4 unspecified spina bifida with hydrocephalus (12.5%), spina bifida combined with meningomyelocele (5%) and spinal bifida occulta (1.25%). We analyzed the subtypes of anencephaly and found that both anencephaly and anencephaly combined spina bifida were not statistically significant ([Table 6](#pone-0086145-t006){ref-type="table"}). However the subtypes of spina bifida were statistically significant in the Q05.1 and Q05.2 ([Table 7](#pone-0086145-t007){ref-type="table"}). The number of samples in Q05.0 (n = 3); Q05.3 (n = 3); Q05.4 (n = 10); spina bifida combined with meningomyelocele (n = 4) and spinal bifida occulta (n = 1) were too less and they were not statistically analyzed.

10.1371/journal.pone.0086145.t005

###### SNPs genotypes frequencies of the 4 SNPs in the 2 subtype groups.

![](pone.0086145.t005){#pone-0086145-t005-5}

  SNP                        Genotype                 Controls (%)   Anencephaly (%)    Spina Bifida (%)
  ----------- -------------------------------------- -------------- ------------------ ------------------
  rs4586354                     TT                     164 (54.1)       52 (53.1)          29 (39.7)
                              CT+CC                    139 (45.9)       46 (46.9)          44 (60.3)
                          *OR*(95%*CI*)                    1         1.04 (0.66,1.65)   1.79 (1.06,3.01)
               *P* [a](#nt112){ref-type="table-fn"}                        0.85              0.027
  rs3783903                     AA                     165 (52.2)       48 (47.5)          26 (32.5)
                              AG+GG                    151 (47.8)       53 (52.5)          54 (67.5)
                          *OR*(95%*CI*)                    1         1.21 (0.77,1.89)   2.27 (1.35,3.81)
               *P* [a](#nt112){ref-type="table-fn"}                        0.41              0.002
  rs2236131                     GG                      181 (58)        47 (47.5)          31 (40.3)
                              AG+AA                    138 (42.3)       52 (52.5)          48 (58.5)
                          *OR*(95%*CI*)                    1         1.45 (0.92,2.28)   2.03 (1.23,3.36)
               *P* [a](#nt112){ref-type="table-fn"}                        0.11              0.008
  rs1740689                     AA                     139 (44.3)       34 (27.3)          21 (27.3)
                              AG+GG                    175 (55.8)       63 (64.9)          56 (72.3)
                          *OR*(95%*CI*)                    1         1.47 (0.92,2.36)   2.12 (1.22,3.67)
               *P* [a](#nt112){ref-type="table-fn"}                        0.11              0.007

Abbreviations: SNP, single-nucleotide polymorphism; *OR*, odds ratio; *CI*, confidence interval.

^a^ *P* values were calculated by *x* ^2^ test 2×2 contingency table for genotype distribution.

10.1371/journal.pone.0086145.t006

###### SNPs genotypes frequencies of the 4 SNPs in the subtype of anencephaly.

![](pone.0086145.t006){#pone-0086145-t006-6}

  SNP                        Genotype                 Contol (%)   Total Anencephaly (%)   Anencephaly & SB[\*](#nt113){ref-type="table-fn"}(%)   Only Anencephaly(%)
  ----------- -------------------------------------- ------------ ----------------------- ------------------------------------------------------ ---------------------
  rs4586354                     TT                    164 (54.1)         52 (53.1)                              33 (52.4)                              12 (52.2)
                              CT+CC                   139 (45.9)         46 (46.9)                              30 (47.6)                              11 (74.8)
                           *OR*(95%CI)                    1          1.04 (0.66,1.65)                         1.3 (0.75,2.2)                        1.02 (0.46,2.5)
               *P* [a](#nt115){ref-type="table-fn"}                        0.85                                    0.34                                  0.85
  rs3783903                     AA                    165 (52.2)         48 (47.5)                              30 (47.6)                               11 (44)
                              AG+GG                   151 (47.8)         53 (52.5)                              33 (52.4)                               14 (56)
                          *OR*(95%*CI*)                   1          1.21 (0.77,1.89)                         1.2 (0.7,2.1)                          1.4 (0.6,3.5)
               *P* [a](#nt115){ref-type="table-fn"}                        0.41                                    0.5                                    0.4
  rs2236131                     GG                     181 (58)          47 (47.5)                              33 (53.2)                              10 (41.6)
                              AG+AA                   138 (42.3)         52 (52.5)                              29 (46.8)                              14 (58.4)
                          *OR*(95%*CI*)                   1          1.45 (0.92,2.28)                        1.15 (0.67,1.9)                         1.8 (0.8,4.2)
               *P* [a](#nt115){ref-type="table-fn"}                        0.11                                    0.6                                   0.15
  rs1740689                     AA                    139 (44.3)         34 (27.3)                              20 (32.8)                              8 (34.8)
                              AG+GG                   175 (55.8)         63 (64.9)                              41 (67.2)                              15 (65.2)
                          *OR*(95%*CI*)                   1          1.47 (0.92,2.36)                         1.63 (0.9,2.9)                        1.49 (0.6,3.6)
               *P* [a](#nt115){ref-type="table-fn"}                        0.11                                    0.1                                   0.37

Spina Bifida.

Abbreviations: SNP, single-nucleotide polymorphism; *OR*, odds ratio; *CI*, confidence interval.

*P* values were calculated by *x* ^2^ test 2×2 contingency table for genotype distribution.

10.1371/journal.pone.0086145.t007

###### SNPs genotypes frequencies of the 4 SNPs in the subtype of spina bifida.

![](pone.0086145.t007){#pone-0086145-t007-7}

  SNP                        Genotype                 Controls (%)   Spina Bifida (%)   Thoracic spina bifida with hydrocephalus (%)   Lumbar spina bifida with hydrocephalus (%)
  ----------- -------------------------------------- -------------- ------------------ ---------------------------------------------- --------------------------------------------
  rs4586354                     TT                     164 (54.1)       29 (39.7)                         7 (30.4)                                      13 (37)
                              CT+CC                    139 (45.9)       44 (60.3)                        16 (69.6)                                      22 (63)
                          *OR*(95%*CI*)                    1         1.79 (1.06,3.01)                  2.6 (1.1,6.7)                                  2 (0.97,4.1)
               *P* [a](#nt117){ref-type="table-fn"}                       0.027                             0.03                                         0.042
  rs3783903                     AA                     165 (52.2)       26 (32.5)                        10 (41.6)                                     10 (28.6)
                              AG+GG                    151 (47.8)       54 (67.5)                        14 (58.4)                                     25 (71.4)
                          *OR*(95%*CI*)                    1         2.27 (1.35,3.81)                  1.5 (0.6,3.5)                                 2.7 (1.2,5.8)
               *P* [a](#nt117){ref-type="table-fn"}                       0.002                             0.2                                          0.006
  rs2236131                     GG                      181 (58)        31 (40.3)                         7 (31.8)                                     12 (34.3)
                              AG+AA                    138 (42.3)       48 (58.5)                        15 (68.2)                                     23 (65.7)
                          *OR*(95%*CI*)                    1         2.03 (1.23,3.36)                  2.8 (1.14,7.0)                                2.5 (1.26,5.2)
               *P* [a](#nt117){ref-type="table-fn"}                       0.008                            0.027                                         0.009
  rs1740689                     AA                     139 (44.3)       21 (27.3)                          6 (25)                                       9 (25.6)
                              AG+GG                    175 (55.8)       56 (72.3)                         18 (75)                                      26 (74.4)
                          *OR*(95%*CI*)                    1         2.12 (1.22,3.67)                  2.3 (0.9,6.1)                                 2.3 (1.0,5.1)
               *P* [a](#nt117){ref-type="table-fn"}                       0.007                             0.05                                          0.04

Abbreviations: SNP, single-nucleotide polymorphism; *OR*, odds ratio; *CI*, confidence interval.

*P* values were calculated by *x* ^2^ test 2×2 contingency table for genotype distribution.

Prediction Transcription Factor and Function Tests {#s3c}
--------------------------------------------------

In this study, we predicted the binding capacity of the different genotypes of the four tag SNPs to potential transcription factor using the bioinformatics method and found that the AA genotype of the rs3783903 was located in the conserved sequence of approximate transcription factors AP-1, and there were not any other predicted transcription factor sites in the oligo of rs3783903. The other 3 sites were located in the non-conserved sequences of the transcription factor binding sites. Then we applied EMSA to detect that whether the rs3783903 polymorphism could change the binding ability of the sequence to the transcription factor AP-1.

The Wt-probe containing the AP-1 DNA-binding consensus site was incubated with the nuclear extracts from HeLa cell, shown in [Figure. 2](#pone-0086145-g002){ref-type="fig"}. To be certain that AP-1 is truly binding, AP-1 was incubated with an anti-c-fos and anti-c-jun antibodies with a supershift. Results showed anti-c-fos and anti-c-jun antibodies abrogated the AP-1 biding. Besides, when the unlabeled mutant probes were added to the wild-type labeled probes and the mutant probes failed to compete with the wild-type probes for AP-1 binding. Results showed a different allelic binding capacity of AP-1 in the intron region of the *ITPK1*, which was affected by an A→G exchange. Results suggested that the polymorphism affect the transcription factor binding ability. Therefore, it might regulate the expression and transcription of the *ITPK1* gene.

![The Comparison of Wt-Oligos and Mut-Oligos in the ability of transcription factors combination.\
Line 1, the blank control without the nuclear extracts from HeLa cell; Line 2, the Biotin Wt-probe were incubated with the nuclear extracts from HeLa cell; Line 3--4, competition was also performed using Cold Wt Oligos and Cold Mt Oligos; Line 5, the negative control of supershift line, incubated with IgG; Line 6--7, performed with antibodies specific for c-fos, c-jun; Line 8--10, the Mut-probe were showed for the control. These results showed a different allelic binding capacity of AP-1 in rs3783903 of the *ITPK1*, which is affected by an A→G exchange.](pone.0086145.g002){#pone-0086145-g002}

The Concentration of the Maternal Plasma IP~6~ {#s3d}
----------------------------------------------

[Table 8](#pone-0086145-t008){ref-type="table"} showed that the plasma IP~6~ levels for the different genotypes between control and case were significant difference. The maternal plasma IP~6~ concentrations in the spina bifida subgroup were 7.1% lower than the control group (136.67 vs. 147.05 ngmL−1, P\<0.05). Besides, compared with the other genotypes, mothers with the GG genotype had the lowest plasma IP~6~ levels, and the difference was significant (*P*\<0.05).

10.1371/journal.pone.0086145.t008

###### IP~6~ levels in plasma samples from maternal rs3783903 (values expressed in ng mL^−1^).

![](pone.0086145.t008){#pone-0086145-t008-8}

           Control (Mean±SD, n[a](#nt118){ref-type="table-fn"})   Case (Mean±SD, n[a](#nt118){ref-type="table-fn"})   *P* [b](#nt119){ref-type="table-fn"}   Total [c](#nt120){ref-type="table-fn"}   *P* [c](#nt120){ref-type="table-fn"}
  ------- ------------------------------------------------------ --------------------------------------------------- -------------------------------------- ---------------------------------------- --------------------------------------
  AA                         150.95±20.4 (20)                                     140.2±17.98 (20)                                   0.041                             145.58±19.85 (40)             
  AG                        149.05±20.44 (20)                                      138.4±18.8 (20)                                   0.049                             143.73±20.11 (40)                             0.634
  GG                        141.15±18.91 (20)                                     131.4±14.79 (20)                                   0.033                              136.28±17.4 (40)                              0.01
  Total                      147.05±19.94(60)                                     136.67±17.29(60)                                   0.001                                                           

n refered to the number of subjects.

Student's test was used to calculate the *P* values (control VS case).

Analysis of variance was used to calculate the *P* values and the GG genotype is significant different than other genotypes (*P* = 0.01).

The Difference of *ITPK1* rs3783903 Expression in the 60 Healthy Women {#s3e}
----------------------------------------------------------------------

RT-PCR was performed to examine whether different mRNA expression of rs3783903 alleles was involved in SNP-induced levels of *ITPK1* RNA ([Figure. 3](#pone-0086145-g003){ref-type="fig"}). The value was defined as the expression ratio of *ITPK1* to GAPDH. The expression of *ITPK1* was decreased significantly in mutant type of rs3783903 compared with wild type (GG: AA = 0.59; *P*\<0.05).

![The expression of *ITPK1* gene using quantitative real-time PCR (\**P*\<0.05).\
The expression of *ITPK1* was decreased significantly in mutant type of rs3783903 compared with wild type (GG: AA = 0.59; *P*\<0.05).](pone.0086145.g003){#pone-0086145-g003}

Discussion {#s4}
==========

The present study suggested that the polymorphism of *ITPK1* might be a genetic risk factor for NTDs, which provides a clue for elucidating the mechanism of NTDs induced by *ITPK1* polymorphism. The risk SNPs in *ITPK1* gene might be an indicator of the susceptibility to NTDs during the prenatal examination and serve as an individualized strategy to prevent NTDs.

As a maternal nutrition factor, inositol plays a vital role in embryo development and especially in prevention of NTDs [@pone.0086145-Uldry1]. During embryo development, inositol can be produced as L-myo-inositol-1-phosphate from D-glucose 6-phosphate [@pone.0086145-Majumder1], and it can be derived from maternal placenta which is the major source [@pone.0086145-Scioscia1]. In the present study, we tested the concentration of maternal IP6 level to determine the relationship between various genotypes of rs3783903. Results showed that the plasma IP~6~ concentrations in spina bifida group were lower than that in control (*P*\<0.05). IP~6~ levels in the GG sub-genotype of rs3783903 was significantly lower than that in groups of other genotypes (*P*\<0.05). The *ITPK1* is a key and the rate-limiting enzyme in the synthesis of IP~4~, IP~5~ and IP~6~ in mammalian cells [@pone.0086145-Theibert1]. Deficiency of the key enzymes in the inositol metabolic pathways may decrease the inositol levels in maternal and embryonic cell, leading to the signal transduction disorder and inhibiting the cell movement, proliferation and differentiation. SNPs in the *ITPK1* dynamically regulated the metabolisms of inositol. It is supposed that the decreased maternal inositol levels might affect the placental transfer of inositol, and further affect the development of the fetus.

Our study found that there were no significant differences in general characteristics between groups except that the gestational week in controls was lower than that in cases due to the reason that some pregnant women aborted for non-medical reasons during early pregnancy. So the population we selected was representative. In the study, we found that four tag SNPs in the *ITPK1* gene in NTD-affected pregnancies were significantly associated with NTDs. In further stratified analysis we found that these SNPs were also significant in the spina bifida group (*P*\<0.05, *OR*\>1). Neural tube closure initiated from the tips of the neural ridges which is termed Closure 1. The failure of neural tube in Closure 1 between the midbrain and spine causes craniorachischisis. A partial failure in Closure 1 in the lumbosacral or thoracic region causes the common human birth defect, spina bifida [@pone.0086145-Yamaguchi1]. *ITPK1* is expressed in the neural epithelium and neural crest derivatives during the developing of embryo. The SNPs, induced defects of the key enzymes (*ITPK1*) in inositol metabolic pathway might reduce IP~6~ levels in maternal and embryonic cells, resulting in disorders in the dynamic cellular behaviors in Closure 1 including cell rearrangement, cell proliferation and cell apoptosis. These events would further induce spina bifida. Different NTD phenotypes are related with different dysfunctional events and susceptibility in diverse closure sites during embryonic stages [@pone.0086145-Ahmad1]. It is suggested that spina bifida is more susceptible to the polymorphism of *ITPK1* in NTD-affected pregnancies.

NTDs is a complex etiology involving both environmental and genetic factors [@pone.0086145-Wald1]. The multi-SNPs will affect the genetically susceptibility to diseases. A difference between the haplotypes of polymorphisms can represent the combined effect of the polymorphisms or it can represent the effect of a polymorphism to which the haplotype is in LD [@pone.0086145-Crawford1]. In present study, four different tag SNPs of *ITPK1* gene (rs4586354, rs1740689, rs2236131 and rs3783903) were analyzed and we found that the haplotype TAGA increased a significant risk of NTDs (*OR* = 1.64, 95%*CI* \[1.15--2.33\], *P* = 0.006). The result suggested that CGAG haplotype of *ITPK1* also played a role in modulating the susceptibility to NTDs and might become a genetically susceptible index to provide the experimental evidence in screening the high risk population. The four positive tag SNPs are located in the intronic regions. MACH was used to impute the un-genotyped SNPs in *ITPK1* locus by use of the reference panel ASN data (1000 Genomes Integrated Phase 1). Results showed that the rs882023 (*P* = 1.59E-04), rs10132322 (*P* = 2.52E-04) and rs8013870 (*P* = 3.86E-02) were in the meaningful region of the intron. Polymorphisms in non-coding regions can affect the expression of a genes [@pone.0086145-Knight1]. These SNPs may involve in the process of intron splicing and mRNA transcription and result in the aberrant expression of *ITPK1*. In addition, we predicted the binding capacity of the different genotypes of the positive tag SNPs to the potential transcription factors using the bioinformatics method. Results revealed that that AA genotype of rs3783903 was located in the conserved sequence of AP-1 with more significance than other SNPs. Many reports showed that the genetic variations in introns have impacts on modulations of gene regulation, transcript processing or chromosomal rearrangements [@pone.0086145-Weickert1], [@pone.0086145-Athanasiu1]. Reardon HT et al reported that six SNPs in the first intron of the *FADS2* gene were associated with the expression of *FADS1* [@pone.0086145-Reardon1]. Park TJ et al found that one common polymorphism in Intron 11, rs3816491, was most intensively associated with susceptibility to aspirin-AERD [@pone.0086145-Park1]. The study from Khan Sikandar G also showed that mutations in Intron 3 of the DNA repair gene affected pre-mRNA splicing in association with many skin cancers [@pone.0086145-Khan1]. Kubota Tomoya et al found that a patient with myotonia was caused by a deletion/insertion located in Intron 21 of *SCN4A*, which is an AT-AC type II intron, and the first intronic mutation in a voltage-gatedion channel gene showing a gain-of-function defect [@pone.0086145-Kubota1]. The *ITPK1* gene contains 11 exons, 10 introns (up to 179405 bases) and the alternative splicing, suggests an indispensable role for exonic splicing enhancer sequences in intron. The rs3783903 is located in the conserved sequence of AP-1 distinguished from the other 3 sites. The rs3783903 SNP is associated with the expression levels of *ITPK1*. EMSA assays showed that the nucleo-protein complex was more effectively binded with the AP-1 of "A" allele rather than "G" allele. The rs3783903 SNP acted as a genetically modified factor and regulated alternative splicing in intron. The mRNA levels of *ITPK1* in homozygously mutated NTDs pregnancies were significantly lower than wild type in the healthy pregnant women determined by RT-PCR (*P*\<0.05). The AP-1 combined with the mut-genotype might affect the promoter/enhancer activity that regulates the expression of *ITPK1* gene. Moreover, these might also regulate the splicing of *ITPK1* and influence the inositol metabolism pathway.

To our best knowledge, the present study is the first one to report a tag SNPs based selection of *ITPK1* gene polymorphisms with NTDs risk in the Lvliang mountain area of Shanxi Province in Northern China. The replication of association findings using independently collected samples is very important for the assessment of a positive finding and its generality. Besides, it is essential to provide convincing statistical evidence for association, and to rule out associations due to biases. Therefore, it is beneficial to establish the credibility of a genotype - phenotype association which is derived from candidate-gene or genome-wide association studies [@pone.0086145-Chanock1]. However, replication of our study was challenging because a suitable study would have included the same phenotype, under similar environmental background and the matched age, gravidity, parity, educational level, so a relatively larger population based cohorts would be needed to have sufficient power for replication. In our future works, we will continue to collect specimens to further evaluate data that are generated. Furthermore, our findings need to be validated in different ethnicities with a gene expression functional assay.

Conclusions {#s5}
===========

These results suggested that the maternal rs3783903 of *ITPK1* might be associated with spina bifida, and the allele G of rs3783903 in *ITPK1* gene might affect the AP-1 binding and lead to the decrease of maternal plasma IP~6~ concentration, which might play roles in the pathogenesis of spina bifida in this Chinese population.
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